SUMMARY: Sickle Cell Disease (SCD) or Sickle Cell anemia is an Autosomal Recessive disorder caused by mutations in the hemoglobin beta-globin gene, and affects approximately 100,000 Americans. It is estimated that it affects 1 out of every 365 African-American births and 1 out of every 16,300 Hispanic-American births. The average life expectancy for patients with Sickle Cell Disease in the US is approximately 40-60 years.
HbSS disease or Sickle Cell anemia is the most common Sickle Cell Disease genotype and is associated with the most severe manifestations. HbSS disease is caused by a mutation substituting thymine for adenine in the sixth codon of the beta-globin chain gene. This in turn affects the hemoglobin’s ability to carry oxygen and causes it to polymerize. This results in decreased solubility thereby distorting the shape of the red blood cells, increasing their rigidity and resulting in red blood cells that are sickle shaped rather than biconcave. These sickle shaped red blood cells limit oxygen delivery to the tissues by restricting the flow in blood vessels, leading to severe pain and organ damage (Vaso-Occlusive Crises). Oxidative stress is an important contributing factor to hemoglobin polymerization with polymer formation occurring only in the deoxy state. HbS/b-0 Thalassemia (double heterozygote for HbS and b-0 Thalassemia) is clinically indistinguishable from HbSS disease. Management of Sickle Cell Disease includes pain control, transfusion support and Hydroxyurea. None of the presently available therapies addresses the underlying cause of this disease nor do they fully ameliorate disease manifestations. Allogeneic bone marrow transplantation can cure this genetic disorder, but less than 20% of eligible patients have a related HLA-matched donor. There is therefore a great unmet need to find new therapies for Sickle Cell Disease.
Background: Inflammation and Vasculopathy at the Core of SCD
Sickle cell disease (SCD) is defined by chronic hemolysis, recurrent vaso-occlusion, and a persistent thrombo-inflammatory state. These processes drive episodic pain crises, progressive end-organ damage, cardiopulmonary complications, and premature mortality. Despite advances in disease-directed therapies, vascular dysfunction, oxidative stress, and systemic inflammation remain central, and incompletely addressed features of SCD pathophysiology.
Glucagon-Like Peptide-1 receptor agonists (GLP-1a), widely used in metabolic disease, have demonstrated pleiotropic effects beyond glycemic control. Preclinical and translational studies suggest GLP-1a exert anti-inflammatory, endothelial-protective, and antithrombotic effects through modulation of NF-κB, ERK/AMPK, and JAK/STAT signaling pathways, suppression of oxidative stress, macrophage polarization, and reduced platelet aggregation. Importantly, GLP-1 receptor activation in monocytes, macrophages, and neutrophils has been shown to attenuate NF-κB signaling and limit NLRP3 inflammasome priming, mechanisms highly relevant to SCD biology. Given these overlapping pathways of vascular injury and inflammation in SCD, investigators hypothesized that GLP-1a therapy could favorably modify the vascular and inflammatory milieu in SCD.
Study Design: Real-World Evidence from a Global Cohort
To explore this hypothesis, researchers conducted a retrospective, Propensity Score–Matched cohort study using the TriNetX Analytics Network, a global research platform aggregating de-identified data from more than 275 million patients worldwide.
The analysis identified over 238,000 individuals treated for SCD between 2005 and 2022, including 5,638 patients exposed to GLP-1a therapy. After 1:1 Propensity Score Matching, accounting for demographics, SCD-directed therapies, comorbidities, laboratory values (including HbA1c), and cardiovascular medications, 4,807 matched pairs were included in the final analysis.
The cohorts were well balanced, with a mean age in the early 50s, 73% female representation, and similar racial distribution. Comorbidities such as hypertension, diabetes, and overweight/obesity were comparable between groups. Mean follow-up was 3 years, and the average duration of GLP-1a exposure among users was approximately 136 days.
Primary outcomes included all-cause mortality, sickle cell crisis, ischemic stroke or Transient Ischemic Attack (TIA), and Venous ThromboEmbolism (VTE). Secondary outcomes encompassed health care utilization and major organ complications, including hospitalization, ICU admission, Acute kidney injury (AKI), thrombocytopenia, Heart Failure (HF), Pulmonary Fibrosis (PF), Pulmonary Hypertension (PH), and Myocardial Infarction (MI).
Results: Consistent Risk Reduction Across Clinical Endpoints
GLP-1a use was associated with significant reductions across all primary outcomes. Most notably, patients receiving GLP-1a experienced a markedly lower risk of all-cause mortality compared with non-users (2.5% vs. 7.0%; OR 0.33; 95% CI, 0.27–0.41). Rates of sickle cell crisis were also reduced (3.5% vs. 4.3%), as were ischemic stroke/TIA and VTE events.
Beyond these Primary endpoints, GLP-1a therapy was linked to broad reductions in secondary outcomes and health care utilization. Patients receiving GLP-1a demonstrated lower rates of hospitalization and ICU admission, along with significantly reduced risks of AKI, thrombocytopenia, HF, PH, PF, and MI. Collectively, these findings suggest potential benefits spanning hematologic, cardiovascular, renal, and pulmonary domains.
Clinical Interpretation: A Potential Disease-Modifying Signal
While causality cannot be established due to the retrospective, observational design, the consistency and magnitude of benefit across multiple clinically meaningful outcomes are notable. Investigators acknowledged limitations inherent to Real-World Data, including reliance on ICD coding and limited clinical granularity, which precluded detailed phenotyping or assessment of disease severity and treatment sequencing.
Importantly, concerns surrounding GLP-1a–associated dehydration and its theoretical potential to exacerbate sickling were not reflected in increased crisis rates; in fact, sickle cell crises were less frequent among GLP-1a users. The observed reductions in cardiopulmonary complications may reflect downstream benefits of attenuated inflammation, reduced vaso-occlusion, and improved endothelial function.
Implications and Future Directions
These findings provide compelling, hypothesis-generating evidence that GLP-1 receptor agonists may confer disease-modifying benefits in SCD when used as an adjunct to existing therapies. Beyond individual patient outcomes, reductions in hospitalization and ICU utilization suggest a meaningful impact on overall health care burden.
Prospective, randomized clinical trials will be essential to confirm these observations, clarify optimal patient selection, and define safety considerations specific to the SCD population. If validated, GLP-1a therapy could represent a novel strategy targeting the inflammatory and vasculopathic underpinnings of sickle cell disease.
Key Takeaways
- GLP-1 receptor agonist use was associated with significantly lower all-cause mortality in patients with SCD.
- Reduced risks of sickle cell crisis, ischemic stroke/TIA, and Venous Thromboembolism were observed.
- GLP-1a therapy was linked to fewer hospitalizations, ICU admissions, and cardiopulmonary complications.
- Findings support prospective trials to evaluate GLP-1a as a potential disease-modifying adjunct in SCD management.
Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications. Cheema AY, Munir M, Mandala A, et al. Presented at: ASH Annual Meeting and Exposition; Dec. 6-9, 2025; Orlando. Abstract 2970.
